Research Overview
· Last Reviewed May 3, 2026· PSI Editorial Board· IndependentCan Peptides Help Me Lose Body Fat?
The honest map across 6 fat loss scenarios — body composition context, what's been studied, and where validated obesity medicine still rules.
WHICH FAT LOSS CONTEXT?
Fat Loss Context
Animal Studies
Human Trials
Total body fat reduction in obesity
primary fat loss context
Body recomposition with lean mass preservation
fat-to-lean ratio context
Visceral fat in HIV-associated lipodystrophy
FDA-approved Tesamorelin indication
Type 2 diabetes with adiposity
T2DM + body fat context
Athletic body composition (cutting cycles)
non-obese fat reduction
Cardiovascular risk reduction with adiposity
ASCVD + fat context
Severe obesity (BMI 35+ with comorbidities)
bariatric surgery candidacy
Adjunct after lifestyle and validated therapy optimized
validated foundation first
How counts are scaled → · Tap any row to see the studies →
Quick Answer
Fat loss has well-characterized validated approaches. Foundations include accurate body composition assessment, lean mass preservation strategy, and individualized therapy matching per obesity medicine guidelines. Validated approaches include FDA-approved GLP-1 RAs (Wegovy, Saxenda) and dual agonists (Zepbound). Additional foundations include caloric deficit, resistance training to preserve lean mass, adequate sleep, stress management, and bariatric surgery for severe obesity.
Tirzepatide anchors the fat loss conversation on this page. The compound holds FDA approval (Zepbound) for chronic weight management. Phase 3 SURMOUNT trials report approximately 20-22 percent body weight loss with body composition substudies suggesting favorable fat-to-lean ratio.
Semaglutide is FDA-approved (Wegovy) for chronic weight management with substantial fat loss in Phase 3 STEP trials. Body composition analyses document fat reduction alongside some lean mass loss.
Tesamorelin holds FDA approval (Egrifta) for HIV-associated lipodystrophy. The GHRH analog produces 15-20 percent CT-measured visceral fat reduction in Phase 3 trials.
Retatrutide is an investigational triple GIP/GLP-1/glucagon receptor agonist. The Phase 2 trial reported 24.2 percent body weight loss including fat-specific reduction at 48 weeks. Phase 3 TRIUMPH enrolling.
AOD-9604 is community-discussed for fat loss with thin direct human evidence. Phase 2 trials produced negative weight loss results.
The honest framing: three peptides hold FDA approvals with substantial Phase 3 fat loss evidence. Lean mass preservation is an active research question. For broader context, see Peptides for Belly Fat and Peptides for Visceral Fat.
Tirzepatide vs Semaglutide for fat loss with lean mass preservation
Comparing the two FDA-approved chronic weight management options on body composition
Semaglutide (Wegovy) holds FDA approval based on Phase 3 STEP trials reporting approximately 15 percent body weight loss over 68 weeks. Body composition analyses document substantial fat reduction. Some lean mass loss is also documented alongside fat loss. The lean mass preservation question is an active research area in the GLP-1 RA class.
Tirzepatide (Zepbound) holds FDA approval based on Phase 3 SURMOUNT trials reporting approximately 20-22 percent body weight loss over 72 weeks. SURMOUNT-5 head-to-head demonstrated greater weight loss with tirzepatide than semaglutide. Body composition substudies suggest fat-to-lean ratio considered favorable, though most direct comparisons remain cross-trial. Once-weekly subcutaneous administration.
PSI's reading: both peptides hold validated FDA-approved chronic weight management indications with substantial Phase 3 evidence. Tirzepatide demonstrates larger effect sizes and may favor better fat-to-lean ratio in body composition substudies. Resistance training during fat loss therapy supports lean mass preservation regardless of compound choice. Patient selection considers tolerance, contraindications, and individualized factors under obesity medicine guidance.
Tesamorelin vs GLP-1 RAs for visceral fat targeting
VAT-specific FDA approval vs broad chronic weight management
Tesamorelin (Egrifta) holds FDA approval specifically for HIV-associated lipodystrophy with central abdominal fat accumulation. Phase 3 trials used CT-quantified visceral adipose tissue as primary endpoint with 15-20 percent VAT reduction over 26 weeks. The mechanism is GHRH analog stimulation of endogenous GH with effects on visceral fat lipolysis. The approval is narrow and population-specific.
Tirzepatide and Semaglutide hold FDA approvals for chronic weight management without VAT-specific imaging endpoints. Phase 3 trials measured total body weight loss as primary endpoint with body composition substudies demonstrating fat reduction across compartments. Effect sizes are substantial across body fat as a whole.
PSI's reading: for HIV-associated lipodystrophy with imaging-confirmed VAT reduction, Tesamorelin is the validated FDA-approved option. For broader fat loss in obesity, FDA-approved GLP-1 RAs and dual agonists hold validated chronic weight management positioning. Obesity medicine, endocrinology, or HIV care specialty guidance ensures appropriate matching.
Retatrutide vs Tirzepatide for fat loss (investigational vs FDA-approved)
Phase 2 effect sizes vs Phase 3 validated approval
Tirzepatide (Zepbound) holds FDA approval based on Phase 3 SURMOUNT-1 with 22.5 percent body weight loss over 72 weeks. SURMOUNT-5 head-to-head demonstrated greater weight loss than semaglutide. The compound is the largest-effect-size FDA-approved chronic weight management option in 2026.
Retatrutide is investigational with Phase 2 trial demonstrating 24.2 percent body weight loss at 48 weeks at the 12mg dose. The triple receptor mechanism (GIP/GLP-1/glucagon) with glucagon-component appetite-independent fat oxidation may exceed dual receptor effect sizes pending Phase 3 readout. Phase 3 TRIUMPH program is enrolling. Cross-trial comparison suggests Retatrutide may exceed Tirzepatide effect sizes. Head-to-head Phase 3 data is not yet available. Not FDA-approved as of 2026.
PSI's reading: Tirzepatide is the validated FDA-approved largest-effect-size chronic weight management option. Retatrutide Phase 2 evidence is promising for next-generation effect sizes pending Phase 3 readout. Patients pursuing fat loss in 2026 should work with FDA-approved options under obesity medicine guidance. TRIUMPH trial enrollment may be appropriate for some patients pursuing investigational therapy.
Peptides vs lifestyle and bariatric surgery for fat loss
Where peptides fit alongside the broader fat loss toolkit
Lifestyle interventions for fat loss have substantial evidence. Caloric deficit through dietary intervention drives overall weight loss including fat. Resistance training preserves lean mass during fat loss and supports body composition. Aerobic exercise improves cardiometabolic health and supports fat oxidation. Adequate sleep prevents cortisol-driven adiposity. Stress management reduces cortisol-mediated fat accumulation. Mediterranean and DASH diet patterns have evidence for body composition.
Bariatric surgery (gastric sleeve, gastric bypass, others) has substantial Phase 3 and observational evidence for severe obesity (BMI 40+ or BMI 35+ with comorbidities) with effect sizes substantially larger than pharmacotherapy. Validated for appropriate candidates under bariatric surgery specialty guidance.
PSI's reading: lifestyle foundations are essential alongside any pharmacotherapy. Resistance training is particularly important for lean mass preservation during pharmacotherapy-driven fat loss. FDA-approved GLP-1 RAs and dual agonists produce meaningful fat loss as additive to lifestyle interventions, not substitutes. Bariatric surgery applies to severe obesity. Comprehensive fat loss care integrates lifestyle, pharmacotherapy, and surgical options as indicated.
The Compounds, Ranked by Evidence
Ordered by strength of controlled human data, not popularity.
Of the 5 peptides discussed for fat loss, three carry FDA approvals with substantial Phase 3 evidence. Tirzepatide holds FDA approval (Zepbound) for chronic weight management with fat-to-lean ratio considered favorable in body composition substudies. Semaglutide holds FDA approval (Wegovy) for chronic weight management with extensive STEP trial evidence. Tesamorelin holds FDA approval (Egrifta) specifically for HIV-associated visceral fat. Retatrutide is in Phase 2/3 development with reported 24.2 percent body weight loss in Phase 2. AOD-9604 had Phase 2 negative weight loss results. Validated obesity medicine including GLP-1 RAs, lifestyle, and bariatric surgery dominates evidence-graded fat loss care.
Tirzepatide
FDA-approved Zepbound for chronic weight management with SURMOUNT 20-22 percent body weight loss and body composition substudies suggesting favorable fat-to-lean ratio.
Counts are PubMed-indexed papers and registered clinical trials. Scale: Strong 10+, Moderate 4–9, Limited 1–3, None 0. Methodology →
| Context | Animal Studies | Human Trials |
|---|---|---|
Chronic weight management with fat reduction FDA-approved Zepbound indication | 8 Dual GIP/GLP-1 receptor agonist weight loss effects with body composition changes. | 6 Phase 3 SURMOUNT trials supporting FDA approval; 20-22 percent body weight loss with body composition substudies. Jastreboff 2022 |
Head-to-head vs Semaglutide comparative effect size context | 4 Comparative effect sizes in animal models. | 2 SURMOUNT-5 head-to-head trial supporting greater weight loss vs Semaglutide. Aronne 2024 |
Semaglutide
FDA-approved Wegovy for chronic weight management with STEP 15 percent body weight loss. Also FDA-approved cardiovascular risk reduction. Some lean mass loss documented.
| Context | Animal Studies | Human Trials |
|---|---|---|
Chronic weight management with fat reduction FDA-approved Wegovy indication | 8 GLP-1 receptor agonist weight loss effects with body composition changes in animal models. | 6 Phase 3 STEP trials supporting FDA approval; 15 percent body weight loss with fat-specific reduction. Wilding 2021 |
Cardiovascular risk reduction FDA-approved Wegovy CV indication | 6 Cardiovascular protective effects in animal models. | 6 Phase 3 SELECT trial supporting CV approval; 20 percent MACE reduction. Lincoff 2023 |
Tesamorelin
FDA-approved Egrifta for HIV-associated lipodystrophy with Phase 3 CT-measured visceral fat reduction. Only VAT-specific FDA approval.
| Context | Animal Studies | Human Trials |
|---|---|---|
HIV-associated CT-measured VAT reduction FDA-approved Egrifta indication with imaging endpoint | 6 GHRH analog effects on body composition with visceral fat targeting in animal models. | 6 Phase 3 trials supporting FDA approval; 15-20 percent CT-measured visceral fat reduction over 26 weeks. Falutz 2007 |
Off-label non-HIV visceral fat off-label use context | 4 Visceral fat reduction in non-HIV animal models. | 2 Limited off-label use studies; absent Phase 3 outcome trials in non-HIV populations. |
Retatrutide
Investigational triple agonist with Phase 2 24.2 percent body weight loss including fat-specific reduction. Phase 3 TRIUMPH enrolling. Not FDA-approved.
| Context | Animal Studies | Human Trials |
|---|---|---|
Phase 2 fat loss with body composition data investigational triple agonist | 6 Triple receptor agonist weight loss effects with enhanced energy expenditure in animal models. | 4 Phase 2 obesity trial with 24.2 percent body weight loss including fat-specific reduction at 48 weeks. Jastreboff 2023 |
Phase 2 T2DM glucose and weight effects T2DM development context | 4 Glucose regulation and weight loss in diabetic models. | 2 Phase 2 T2DM trial supporting Phase 3 TRIUMPH enrollment. Rosenstock 2023 |
AOD-9604
Phase 2 trials produced negative weight loss results. Pharmaceutical development discontinued. Community use despite negative evidence.
| Context | Animal Studies | Human Trials |
|---|---|---|
Fat loss (Phase 2 negative) primary indication on this page | 8 Lipolytic effects in obese animal models. Heffernan 2001 | 4 Phase 2 trials produced negative weight loss results vs placebo; pharmaceutical development discontinued. |
What's Marketed vs What's Studied
6 common claims, corrected.
“Peptides specifically melt fat without overall weight loss.”
FDA-approved GLP-1 RAs and dual agonists produce overall weight loss with proportional reductions across body compartments including fat. Effect sizes are not specifically targeted to fat over other compartments. Tesamorelin within HIV-associated lipodystrophy approval has more visceral-fat-targeted effects. Spot-fat-reduction marketing overstates the evidence base.
“GLP-1 RAs exclusively burn fat without lean mass effects.”
Body composition analyses from Phase 3 GLP-1 RA trials document fat reduction alongside some lean mass loss. The lean mass preservation question is an active research area. Tirzepatide may favor better fat-to-lean ratio than semaglutide in body composition substudies. Resistance training during pharmacotherapy supports lean mass preservation regardless of compound choice.
“Retatrutide is the new go-to for fat loss.”
Retatrutide Phase 2 evidence is promising with 24.2 percent body weight loss. The compound is investigational with Phase 3 TRIUMPH program enrolling. Not yet FDA-approved as of 2026. Compounded availability faces FDA enforcement action. Validated FDA-approved options including Tirzepatide, Semaglutide, and Tesamorelin (HIV indication) hold current evidence-graded fat loss positioning.
“AOD-9604 is a proven fat loss peptide.”
AOD-9604 had Phase 2b trials in obesity produce negative weight loss results compared to placebo. Pharmaceutical development was discontinued for obesity indication. Community use persists despite negative trial evidence and is not validated practice. FDA-approved GLP-1 RAs and dual agonists have substantial Phase 3 weight loss evidence.
“GH-axis compounds (CJC-1295, Ipamorelin) drive validated fat loss.”
GH-axis compounds are referenced in fat loss conversations through indirect lipolysis signaling. Direct fat-specific human trial evidence is absent. The fat loss rationale is mechanistic and inferential, derived from GH signaling effects on adipose tissue rather than controlled fat loss trials. FDA-approved GLP-1 RAs and dual agonists have substantial Phase 3 evidence.
“I can lose fat without seeing a doctor using peptides.”
Fat loss in clinical practice requires comprehensive metabolic assessment, screening for comorbid conditions (T2DM, hypertension, dyslipidemia, sleep apnea), and individualized therapy matching. Self-treatment with research-grade peptides bypasses essential clinical evaluation. Always work with obesity medicine, endocrinology, primary care, or HIV care specialty.
If Considering Use, Here Is How to Be Safe
How to evaluate sources, verify quality, and find qualified physicians.
Get comprehensive metabolic assessment and body composition baseline.
BMI, waist circumference, body composition analysis (DEXA, BIA, or imaging), lipid panel, fasting glucose or HbA1c, blood pressure, sleep apnea screening guide therapy matching.
Match FDA-approved indications to your situation.
Wegovy and Zepbound for chronic weight management (BMI 30+ or 27+ with comorbidities). Tesamorelin for HIV-associated lipodystrophy. Mounjaro and Ozempic for T2DM. Specialty guidance ensures appropriate matching.
Optimize lifestyle foundations including resistance training.
Caloric deficit, resistance training to preserve lean mass during fat loss, aerobic exercise, adequate sleep, stress management, adequate dietary protein (1.0-1.6 g/kg per day), and limited alcohol form the validated foundation.
Plan lean mass preservation strategy.
Resistance training during pharmacotherapy supports lean mass preservation. Adequate dietary protein supports lean mass during caloric deficit. Tirzepatide body composition substudies suggest more favorable fat-to-lean ratio than semaglutide.
Consider Phase 3 TRIUMPH trial enrollment for investigational Retatrutide.
Trial enrollment provides monitored access within validated clinical research framework. Compounded Retatrutide outside trials faces FDA enforcement action and lacks safety monitoring.
Consider bariatric surgery evaluation for severe obesity.
Bariatric surgery applies to BMI 40+ or BMI 35+ with comorbidities with effect sizes substantially larger than pharmacotherapy. Bariatric surgery specialty consultation guides candidacy assessment.
Avoid compounds with negative trial evidence.
AOD-9604 had Phase 2 negative weight loss trials. Community use persists despite negative evidence and is not validated practice. FDA-approved options have substantial Phase 3 evidence.
The regulatory landscape for fat loss is dynamic. Phase 3 TRIUMPH (Retatrutide) program is enrolling with potential FDA approval pending readout. Tirzepatide cardiovascular outcome trial (SURMOUNT-MMO) is in progress. New investigational compounds continue Phase 2/3 development. Compounded GLP-1 RAs face regulatory scrutiny following FDA safety communications. PSI tracks these developments and updates this page as material changes occur.
Find a verified physician
PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.
Browse the directoryLearn about the verification process →Common Questions
What is the difference between fat loss and weight loss?
Weight loss measures total body mass change including fat, lean tissue, and water. Fat loss measures adipose tissue reduction specifically. Body composition matters more than scale weight for cardiometabolic and aesthetic outcomes. GLP-1 RAs and dual agonists produce both fat reduction and some lean mass loss; the lean mass preservation question is an active research area. Body composition analysis (DEXA, BIA, or imaging) provides more meaningful fat-specific data than scale weight alone.
Are any peptides FDA-approved for fat loss?
Yes, three peptides hold FDA approvals with fat loss implications. Tirzepatide (Zepbound) is FDA-approved for chronic weight management with substantial fat reduction in SURMOUNT trials. Semaglutide (Wegovy) is FDA-approved for chronic weight management with substantial fat reduction in STEP trials. Tesamorelin (Egrifta) is FDA-approved specifically for HIV-associated visceral fat reduction. Retatrutide is investigational with Phase 3 TRIUMPH enrolling. AOD-9604 had Phase 2 negative weight loss trials.
Should I work with an obesity medicine specialist for fat loss?
Yes for moderate to severe obesity or when initial primary care management is insufficient. Obesity medicine specialty involvement ensures comprehensive metabolic assessment, screening for comorbid conditions (T2DM, hypertension, dyslipidemia, sleep apnea), and individualized therapy matching. Endocrinology specialty also handles fat loss care. Primary care can manage many initial cases. HIV care specialty handles Tesamorelin for FDA-approved indication.
What is the strongest validated fat loss treatment?
Multiple validated approaches have substantial evidence. Tirzepatide (Zepbound) produces approximately 20-22 percent body weight loss in SURMOUNT trials with body composition substudies suggesting favorable fat-to-lean ratio. Semaglutide (Wegovy) produces approximately 15 percent body weight loss in STEP trials. Tesamorelin produces 15-20 percent CT-measured visceral fat reduction in HIV-associated lipodystrophy. Bariatric surgery produces larger effect sizes for severe obesity. Lifestyle interventions including caloric deficit, resistance training, and sleep optimization form the foundation alongside pharmacotherapy.
Does Tirzepatide really preserve lean mass better than Semaglutide?
Body composition substudies from SURMOUNT and STEP trials suggest tirzepatide may favor better fat-to-lean ratio than semaglutide, though most direct comparisons are cross-trial rather than head-to-head. SURMOUNT-5 head-to-head demonstrated greater total weight loss with tirzepatide but did not specifically isolate fat-to-lean ratio differences. Resistance training during pharmacotherapy supports lean mass preservation regardless of compound choice. Both are validated FDA-approved options under obesity medicine guidance.
What about Retatrutide for fat loss?
Retatrutide is an investigational triple agonist (GIP/GLP-1/glucagon) in late Phase 2 / Phase 3 development. The Phase 2 trial reported 24.2 percent body weight loss at 48 weeks at the 12mg dose with body composition analysis including fat-specific reduction. The triple receptor mechanism with glucagon component theoretically targets fat through enhanced energy expenditure plus appetite suppression. Phase 3 TRIUMPH program is enrolling. Not FDA-approved as of 2026. Compounded availability faces FDA enforcement action.
Should I try Retatrutide before it's FDA-approved?
Patients pursuing investigational Retatrutide therapy should consider Phase 3 TRIUMPH trial enrollment for monitored access within validated clinical research framework. Compounded Retatrutide outside clinical trials faces FDA enforcement action and lacks the safety monitoring of formal trial enrollment. Validated FDA-approved options including Tirzepatide, Semaglutide, and Tesamorelin (HIV indication) hold current evidence-graded fat loss positioning. Obesity medicine or endocrinology specialty guidance helps individualized decision-making.
Can I prevent lean mass loss during GLP-1 RA fat loss?
Resistance training during pharmacotherapy supports lean mass preservation. Adequate dietary protein intake (typically 1.0-1.6 g/kg body weight per day per obesity medicine guidance) supports lean mass during weight loss. Tirzepatide body composition substudies suggest more favorable fat-to-lean ratio than semaglutide. The lean mass preservation question is an active research area. Working with obesity medicine, endocrinology, or registered dietitian supports comprehensive lean mass strategy.
Does AOD-9604 actually reduce body fat?
No based on Phase 2 trial evidence. Phase 2b trials of AOD-9604 in obesity produced negative weight loss results compared to placebo over 12 weeks. Pharmaceutical development was discontinued for obesity indication. Community use of AOD-9604 persists despite negative trial evidence but is not validated practice. FDA-approved GLP-1 RAs and dual agonists have substantial Phase 3 evidence.
What about CJC-1295 and Ipamorelin for fat loss?
GH-axis compounds (CJC-1295, Ipamorelin) are referenced in fat loss conversations through indirect lipolysis signaling. CJC-1295 is a GHRH analog with Phase 2 human pharmacokinetic data confirming GH and IGF-1 elevation. Ipamorelin is a selective GH secretagogue with limited human data. Direct fat-specific human trial evidence is absent for both compounds. The fat loss rationale is mechanistic and inferential. FDA-approved GLP-1 RAs and dual agonists hold validated fat loss positioning.
What lifestyle changes have strongest fat loss evidence?
Multiple lifestyle interventions have substantial validated evidence. Caloric deficit through dietary intervention drives overall weight loss including fat. Resistance training preserves lean mass during fat loss. Aerobic exercise improves cardiometabolic health and supports fat oxidation. Adequate sleep prevents cortisol-driven adiposity. Stress management reduces cortisol-mediated fat accumulation. Adequate dietary protein supports lean mass during caloric deficit. Mediterranean and DASH diet patterns have evidence base.
Can I expect fat to come back after stopping GLP-1 RAs?
Discontinuation of GLP-1 RAs typically results in weight regain in published Phase 3 extension data. The STEP-4 trial demonstrated weight regain after semaglutide discontinuation. Long-term sustained therapy is the typical clinical pattern for chronic weight management. Some patients transition to validated maintenance approaches alongside continued lifestyle optimization. Resistance training during and after pharmacotherapy supports body composition maintenance. Obesity medicine specialty guidance helps plan long-term management.
What questions should I ask a doctor about peptides for fat loss?
Ask: (1) What is my comprehensive metabolic assessment and body composition? (2) For my situation, what FDA-approved options apply (Wegovy, Zepbound, Saxenda for obesity; Mounjaro and Ozempic for T2DM; Tesamorelin for HIV-associated lipodystrophy)? (3) Have I optimized lifestyle foundations including caloric deficit, resistance training, sleep, and dietary protein? (4) How do I preserve lean mass during fat loss therapy? (5) Should I consider bariatric surgery evaluation if BMI 35-40+? (6) Is Phase 3 TRIUMPH (Retatrutide) trial enrollment appropriate? (7) How do GLP-1 RA contraindications apply?
Are GLP-1 RAs safer than bariatric surgery for fat loss?
The comparison is not equivalent. Both have substantial validated evidence. GLP-1 RAs have characterized side effects (gastrointestinal symptoms, rare pancreatitis, contraindications in MEN 2 syndrome). Bariatric surgery has surgical and long-term nutritional risks but produces larger sustained effect sizes for severe obesity. Obesity medicine and bariatric surgery specialty guidance helps individualized therapy matching considering BMI, comorbidities, and patient preferences.
Are these peptides legal in the United States?
Tirzepatide (Zepbound, Mounjaro), Semaglutide (Wegovy, Ozempic, Rybelsus), and Tesamorelin (Egrifta) are FDA-approved with established commercial products available by prescription. Retatrutide is investigational; access is through Phase 3 TRIUMPH trial enrollment. AOD-9604 is research-only with limited compounded availability through 503A pharmacies despite negative Phase 2 trial evidence. The FDA has issued safety communications about various compounded peptides. Always work with a licensed prescriber within validated medical framework.
What are the side effects of fat loss peptides?
Tirzepatide and Semaglutide GLP-1 RA and dual agonist side effects include nausea, vomiting, diarrhea, and constipation (typically dose-dependent). Rare side effects include pancreatitis. Personal or family history of medullary thyroid carcinoma and MEN 2 syndrome are absolute contraindications. Tesamorelin side effects include injection site reactions, joint pain, and IGF-1 elevations requiring monitoring. Retatrutide Phase 2 side effects mirror dual agonist class with gastrointestinal symptoms. AOD-9604 has limited human safety data outside negative Phase 2 trials. All peptide use should occur under specialty guidance.
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.